MetaVia Inc. (MTVA) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

38/ 100

GoAI Score

Sell

Valuation

48

Fair Value

Sentiment

59

Mixed

Risk

68

High Risk

Momentum

24

Weakening

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $1.41

$1.39$1.44

52-week range

Current $1.41

$0.966$14.85

Open: $1.415
Previous close: $1.34
Volume: 49.05K
Market cap: 9.29M USD
50-day average: $1.577; -10.59% below average
200-day average: $2.2184; -36.44% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -0.35×
P/B (TTM): 1.23×
P/S (TTM): 0×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%

Financial health

Debt / equity: 0.03×
Altman Z-score: -18.8
Piotroski F-score: 0 of 9

Earnings

EPS beat rate: 40%; 4 beats, 6 misses, 0 met estimates
Average EPS surprise: -182.91%; 10 comparable reports
Latest EPS result: -0.9; Estimate -0.82 · Miss by 9.76%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions

Maxim GroupmaintainBuyMay 19, 2025

MTVA news

prnewswire.comSep 9, 2026

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726 CAMBRIDGE,…

Read source

prnewswire.comAug 6, 2026

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fourth Quarter of 2026 CAMBRIDGE, Mass., Aug. 6,…

Read source

MTVA peers

AMGN

Amgen Inc.

$414.87

+1.82%

GILD

Gilead Sciences, Inc.

$151.17

+2.77%

ISRG

Intuitive Surgical, Inc.

$423.96

+2.06%

VRTX

Vertex Pharmaceuticals Incorporated

$510.08

+1.36%

SNY

Sanofi

$40.07

-0.40%

MRNA

Moderna, Inc.

$225

+14.21%

ETFs holding MTVA

Funds reporting this stock among their holdings, ordered by reported position size.

ETFMarket valueWeightAUMExpense ratioPrice / 1D

Vanguard Extended Market ETFVXF28.75K0.00%95.4B USD0.05%$235+0.80%

Vanguard Extended Market ETFVXF

Market value: 28.75K
Weight: 0.00%
AUM: 95.4B USD
Expense ratio: 0.05%
Price / 1D: $235+0.80%

MetaVia Inc.

MTVA company overview

MetaVia Inc.

MTVA company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Earnings

EPS: actual versus estimate

Analyst ratings

Recent analyst actions

MTVA news

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MTVA peers

ETFs holding MTVA

Continue in GoAI

MTVA company overview

Company profile

Market position

MTVA company overview

MTVA company overview

Company profile

Market position

MTVA company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Earnings

EPS: actual versus estimate

Analyst ratings

Recent analyst actions

MTVA news

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MTVA peers

ETFs holding MTVA

Continue in GoAI